Folke L.
- Country
- Germany
- Department
- MVZ Johanniter Onkologie Bonn-Rhein-Sieg
Research Overview
- Phase 3 Randomized Open‑Label Study of ZL‑1310 versus Investigator‑Chosen Topotecan in Relapsed Small Cell Lung Cancer
- Evaluation of BNT327 Combined with Chemotherapy and Investigational Agents in First-Line Treatment of Non-Small Cell Lung Cancer
- A Phase III, multisite, double-blinded randomized trial of BNT327 in combination with chemotherapy (etoposide/carboplatin) compared to atezolizumab in combination with chemotherapy (etoposide/carboplatin) in participants with first-line extensive-stage small-cell lung cancer
Data & Insights
Has run more than one trial at 87 of 225 partner sites.
Specializations
Oncology Focus
This investigator specializes in the treatment of non-small cell lung cancer, conducting research into advanced therapeutic approaches for this condition.
- Lung Cancer Treatment
- Combined Therapy Approaches
- Advanced Cancer Care
The investigator explores innovative treatment combinations including chemotherapy and novel therapeutic agents.
Therapeutic Innovation
The investigator focuses on evaluating combination therapy strategies for treating lung cancer, including the integration of investigational agents with standard treatments.
- Novel Drug Development
- Treatment Optimization
- Clinical Efficacy Studies
Their work encompasses the assessment of safety and effectiveness of new therapeutic combinations.
Clinical Pharmacology
The investigator studies pharmacokinetics of novel therapeutic agents, examining how these medications interact within the body during cancer treatment.
- Drug Movement Analysis
- Safety Assessment
- Treatment Response Evaluation
Their research includes detailed analysis of drug interactions and therapeutic outcomes in cancer patients.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.